Brief: Design Therapeutics Provides Pipeline Updates And Reports First Quarter 2023 Financial Results
09/05/2023 23:03
Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS PROVIDES PIPELINE UPDATES AND REPORTS
FIRST
QUARTER 2023 FINANCIAL RESULTS
* INITIAL DATA FROM PHASE 1 MULTIPLE-ASCENDING DOSE TRIAL OF
DT-216 FOR FRIEDREICH ATAXIA EXPECTED IN Q3 OF 2023
* $315.4 MILLION IN CASH AND SECURITIES EXPECTED TO SUPPORT
OPERATING RUNWAY THROUGH 2025
* QTRLY LOSS PER SHARE $0.35
* Q1 EARNINGS PER SHARE VIEW $-0.36 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4pvq2B
Further company coverage: DSGN.O
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1